CRISPR/Cas9 technology knocked in the human transferrin receptor apical domain coding sequence into the locus creating a chimeric mouse/human transferring receptor under the control of the endogenous promotor which preserves the native murine transferrin ligand binding domain and retains the majority of Tfrc introns, minimizing potential dysregulation of protein expression and function. (J:325423)